In 2020, while most skincare brands in India followed trends, Dr. Renita Rajan took a different approach. She focused on science, clinical evidence, and a deep understanding of melanin-rich skin.

This vision has attracted strong investor confidence. Bengaluru-based CHOSEN has raised $5 million in a Series A funding round led by Fireside Ventures, with participation from BOLD and Alkemi Growth Capital. The round also received support from angel investor Avnish Anand and leading dermatologists.

But this isn’t just another beauty brand story. CHOSEN centers on the concept of the “exposome,” which looks at how lifestyle and environmental factors affect skin health. Instead of quick fixes, the company offers long-term, clinically supported solutions for issues like pigmentation, aging, and hair health.

Its products reflect this philosophy. From the SAFESCREEN NEXGEN sunscreen to the Sculpt protocol for facial contouring, each product is designed specifically for Indian skin, combining dermatology with daily skincare routines.

What really sets CHOSEN apart is its hybrid model. It connects clinics and consumers; patients start their journey under a dermatologist’s care and continue their treatment through its direct-to-consumer platform. With insights from over 150,000 consultations, the brand has quietly built a solid foundation. Today, its products are prescribed in more than 2,000 clinics, while its digital platform accounts for most of the sales.

Investors are betting on this unique blend of science and growth. As demand increases for dermocosmetics, where skincare meets medicine, CHOSEN is well-positioned at a promising intersection.

With new funding, the company plans to enhance research, broaden its product range, and strengthen its network of dermatologists. It remains committed to its original mission: making evidence-based skincare the standard, not the exception.